Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

2021273 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 22, Issue 9, pp. 1250-1264

Field-Weighted Citation Impact: 19.93